出版者・発行元：Surgical Innovation  

DOI： 10.1177/15533506231160201

Web of Science

Scopus

記述言語：日本語   出版者・発行元：日本VR医学会  

DOI： 10.24764/jsmvr.2022.0_27

CiNii Research

記述言語：英語   出版者・発行元：Journal of Digestive Diseases  

DOI： 10.1111/1751-2980.13122

Web of Science

Scopus

PubMed

記述言語：英語   掲載種別：研究論文（学術雑誌）   出版者・発行元：Cancer Medicine  

Background: Human epidermal growth factor receptor 2 (HER2) is tyrosine kinase receptor that belongs to the ErbB family and is overexpressed on the membrane surface of various cancer cells, including small cell lung cancer (SCLC); however, no HER2 targeted therapy for SCLC have yet been established. Near-infrared photoimmunotherapy (NIR-PIT) is a novel cancer therapy based on photo-absorber, IRDye-700DX (IR700), -antibody conjugates, and near-infrared (NIR) light. Methods: We used HER2-positive SCLC parental cell lines (SBC-3) and its chemoresistant cell lines, and examined therapeutic efficacy of HER2 targeting NIR-PIT using anti HER2 antibody trastuzumab. Results: We found that HER2 expression was upregulated on chemoresistant cell lines, especially cisplatin-resistance (SBC-3/CDDP). In vitro, the rate of cell death increased with the amount of NIR-light irradiation, and it was significantly higher in SBC-3/CDDP than in SBC-3. In vivo, tumor growth was more suppressed in SBC-3/CDDP group than in SBC-3 group, and survival period tended to be prolonged. Conclusion: In this study, we demonstrated that HER2 targeting NIR-PIT using trastuzumab is promising therapy for HER2-positive SCLC, and is more effective when HER2 expression is upregulated due to CDDP resistance, suggesting that the HER2 expression level positively corelated with the efficacy of NIR-PIT.

DOI： 10.1002/cam4.4381

Web of Science

Scopus

PubMed

DOI： 10.1016/j.jtho.2019.08.1120

Web of Science

記述言語：英語   掲載種別：速報，短報，研究ノート等（学術雑誌）   出版者・発行元：Journal of Cardiology Cases  

Transportation of patients with coronavirus disease (COVID)-19 outside isolation rooms should be avoided to prevent further spread of the disease. Here, we report a safe and accurate bedside cannulation method for veno-venous extracorporeal membrane oxygenation (VV-ECMO) in a COVID-19 patient in the intensive care unit. A 71-year-old man was admitted to our hospital and diagnosed as having COVID-19 pneumonia. We decided to initiate VV-ECMO therapy because maintaining blood oxygen saturation was difficult despite the mechanical ventilation. We placed two flat-panel detectors behind the patient's chest and the right inguinal area. We repeatedly imaged and monitored insertion of wires and cannulas using a portable X-ray system. Cannulas were successfully inserted in the appropriate position, and VV-ECMO was initiated without any complications. <Learning objective: Transportation of patients with coronavirus disease outside isolation rooms carries the risk of further spread of the disease. By repeatedly acquiring images using a portable X-ray system, safe and accurate cannulation for veno-venous extracorporeal membrane oxygenation cannulation can be performed at the bedside in the intensive care unit.>

DOI： 10.1016/j.jccase.2021.09.008

Scopus

PubMed

胸部X-P読影の講義後、実際のレントゲンを使用しての読影実習

臨床実習II 第I, II期 学生一名を実習期間を通じて指導　平均4コマ／週程度で担当患者や関連する医学についてDiscussion

臨床実習I 呼吸器内科 木曜午前にMxRセンターにて胸腔穿刺についての講義ならびにシミュレータを使用しての実習